Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
stocks
World’s largest miner overvalued after solid quarter
stocks
Hidden value in an expensive ASX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,024.20 | 27.20 | -0.30% |
| CAC 40 | 8,193.56 | 37.13 | 0.46% |
| DAX 40 | 24,120.01 | 74.89 | -0.31% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,418.16 | 58.30 | -0.56% |
| HKSE | 25,915.20 | 248.04 | -0.95% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 59,140.23 | 445.63 | -0.75% |
| NZX 50 Index | 12,884.93 | 60.67 | -0.47% |
| S&P 500 | 7,137.90 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,793.40 | 26.10 | -0.30% |
| SSE Composite Index | 4,093.25 | 13.01 | -0.32% |